Industry News
Pharmaceutical Industry News
The partnership builds on previous…
The partnership builds on previous work and will expand Lundbeck's use of Eversana's AI Agency platform across its U.S. commercial organization, the companies said.
Frontier Large Language Models…
Frontier Large Language Models have improved. More data became accessible. Neither solved the hardest questions. Here's what decision-grade pharma AI still needs.
The campaign adds older adults to…
The campaign adds older adults to the obesity conversation and is anchored by Lilly's "A Life Covered" short film, which highlights a woman's decades-long weight loss journey.
Courts in Maryland and Washington,…
Courts in Maryland and Washington, D.C., have rejected separate lawsuits by Merck and AstraZeneca against the Centers for Medicare & Medicaid Services' drug price negotiation program.
With the FDA expected to weigh in…
With the FDA expected to weigh in on its kidney transplant drug, imlifidase, shortly before year-end, Hansa Biopharma is mulling over its stock listing options in the U.S.
With its ascent seemingly…
With its ascent seemingly unstoppable in the last few years, automated cell therapy manufacturer Cellares is facing some tough new realities.
Daiichi Sankyo is promoting Ken…
Daiichi Sankyo is promoting Ken Keller to lead a new globally integrated commercialization unit, putting the executive in charge of a key pillar of its push to become a top five oncology company by 2035.
Education and insight company…
Education and insight company Community Health Media curates its content library by centering physicians as "the talent" and centering its content creation on insightful physician-led conversations.
Almost three years into his tenure…
Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a “neuroscience challenger” capable of “punching above its weight.”
Regeneron’s “Science Illuminated”…
Regeneron's "Science Illuminated" podcast series transforms scientific topics into a calming, meditative-style video and audio experience.
Can We Do Anything About Tick-Borne Diseases Like Alpha-Gal Syndrome?
A scientific and civilizational horror story.
Roche will invest $750 million to…
Roche will invest $750 million to double the size of its Genentech unit's manufacturing facility in Hillsboro, Oregon. The new outlay will support the construction of a fill-finish plant that will produce drug-delivery devices, such
Less than a year after the FDA…
Less than a year after the FDA turned down the resubmitted application for the company’s leukemia prospect Dasynoc, Xspray Pharma has again hit a wall at the U.S. regulator.
Moderna’s Shift to Cancer Company Lifts Stock Up 177%
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
China’s investigator-initiated…
China's investigator-initiated trials, once praised for their speediness, have been drawn into scrutiny for a lack of transparency. AstraZeneca and Daiichi Sankyo's Enhertu earned a win in a phase 3 non-small cell lung cancer trial.
Aurinia Pharmaceuticals has struck…
Aurinia Pharmaceuticals has struck a patent infringement settlement with Teva Pharmaceuticals, which should help stave off Teva's proposed generic for its lupus drug, Lupkynis (voclosporin), in the United States until December of 2036. With the
B. Braun Medical—a maker of IV…
B. Braun Medical—a maker of IV solutions for hospitals, among other products—has initiated a recall in the United States and Canada spurred by particulate contamination.
What Is Treatment-Resistant Depression?
If multiple antidepressants haven’t helped, there are other avenues to explore.
Healthcare comms and…
Healthcare comms and commercialization agency Lucid Group has hired Eric Muller as its new chief executive officer.
Boehringer Ingelheim has continued…
Boehringer Ingelheim has continued its rise up patient groups’ ranking of rare disease companies, adding to last year’s gains to cement its status toward the top of the leaderboards. But the German drugmaker failed to